Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: Hims | History Defined

3 Sectors to Buy While They're Down and 1 to Walk Away From

Jeff Clark and Andy Swan share three beaten-down sectors with contrarian upside and one popular sector to avoid, plus specific stock picks in financials, healthcare, and software.

MarketBeat

MarketBeat Week in Review – 03/09 - 03/13

Stocks moved higher this week despite uncertainty over the Iran conflict and oil prices; economic indicators point to no change in interest rates next week

MarketBeat

Should You Chase the Rally in Hims & Hers Stock Today?

Hims & Hers shares extend gains as Eli Lilly warns impurity it discovered in compounded versions of its weight-loss drug has health implications. Here’s why HIMS stock isn’t worth owning here.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal

Hims & Hers shares surged 46% after partnering with Novo Nordisk to offer FDA-approved Ozempic and Wegovy, moving away from compounded GLP-1 alternatives.

MarketBeat

Novo Nordisk and Hims & Hers Turn Patent Dispute Into Business Opportunity

Novo Nordisk drops its lawsuit against Hims & Hers as the companies partner to offer FDA-approved Wegovy and Ozempic through the telehealth platform.

International Business Times

Stocks Recover as Oil Retreats From $119: Stock Market Today

How high the price of crude oil rises and how long it stays there are critical questions for market participants and policymakers alike.

Kiplinger

Hims & Hers Stock Is Challenging Its 50-Day Moving Average. Should You Bet on a Turnaround Here?

Hims & Hers shares soared as Novo Nordisk dropped its GLP-1 lawsuit. But there’s reason to still sell HIMS stock today. Find out more!

Barchart

Read news from The Economist, FT, and more,
with one subscription

Novo Nordisk drops lawsuit over weight loss medications, enters collaboration with online pharmacy

The news sent shares of Hims & Hers Health Inc. soaring by more than 40% in Monday morning trading

The Independent UK

MarketBeat Week in Review – 02/23 - 02/27

Technology stocks continue to be under pressure, and is flowing into defensive assets; investors should expect more volatility, which can create opportunities

MarketBeat

Hims & Hers in Free Fall: Why Analysts See Nearly 150% Upside

HIMS is down 48% in the past month following a Novo Nordisk lawsuit. But, analysts expect record revenue when the company reports earnings this month.

MarketBeat

As Hims & Hers Gets Hit With Major Wegovy Loss, Should You Buy the Dip in Deeply Oversold HIMS Stock?

Hims & Hers shares crater as Novo Nordisk files a lawsuit against the telehealth firm. BofA analysts see significant further downside in HIMS stock.

Barchart

Hims & Hers drops plan for knockoff of Novo Nordisk's new Wegovy weight loss pill

Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two days after it announced the new drug

The Independent UK

Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut

Investors had little time to celebrate Eli Lilly's huge post-earnings gain. While Hims & Hers Health knocked shares down, LLY remains a healthcare stalwart.

MarketBeat

US health company launches weight-loss pill that Novo Nordisk calls an 'untested knockoff'

The American telehealth company announced the launch of a compounded weight-loss pill for €41, drawing criticism from Novo Nordisk, the Danish company behind the weight-loss drug Wegovy, which called the product an “untested knockoff.”

Euronews

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Hims & Hers launches copy of Wegovy pill, prompting legal threats from drugmaker Novo Nordisk

Telehealth company Hims & Hers is launching a cheaper, off-brand version of the blockbuster weight loss pill Wegovy

Benzinga

What's Going On With Shares Of Hims & Hers Health Thursday?

Shares of Hims Hers Health, Inc. (NASDAQ:HIMS) are trending Thursday morning. The San Francisco-based telehealth company announced an international expansion.

MarketBeat

Hims, Block, and NRG Just Launched Huge Stock Buybacks

Buyback capacity just got a big-time boost at Hims, Block, and NRG Energy. The three firms authorized more than $8 billion in buybacks combined.

MarketBeat

HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?

Hims & Hers Health may only generate a fraction of its competitors revenue, but its fiscal management and exponential growth point to a very bright future.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Hims & Hers Introduces Labs With Annual Plans For Comprehensive Testing

Hims Hers Health, Inc. (NYSE:HIMS) announced the launch of Labs, a new way for customers to understand their overall health and identify ways to improve and maintain it.

Benzinga

Options Corner: Hims & Hers Health's Downturn Presents A Compelling Opportunity For Quants

One of the more popular ideas floating around on Wall Street, Hims Hers Health Inc (NYSE:HIMS) has largely benefited from the general ascendancy of the telehealth business model, along with strong demand for weight-loss treatments. However, it's also a speculative investment, with the wellness platform facing a crowded digital health…

MarketBeat

Why Hims & Hers Stock May Be a Buy After Mixed Q3 Results

Hims & Hers Health delivered a mixed earnings report and announced a potential Wegovy partnership with Novo Nordisk; the downside risk to HIMS stock looks low.

Benzinga

Stock Market Today: Dow Jones, Nasdaq Futures Rise After Stellar October Gains— Micron Technology, Palantir, Hims & Hers In Focus (UPDATED)

Editor’s Note: The future prices of benchmark tracking ETFs and the headline were updated in the story.

The Independent UK

United Airlines pilot accused of DUI sues airline for racial discrimination because they won’t let him fly

The former United pilot says the airline discriminated against him based on a perceived disability and his race

MarketBeat

Hims & Hers Short Interest Nears All-Time High, Buy The Dip?

Hims & Hers stock is falling well off its 52-week highs, as bears lean on the CEO's scheduled sale that just took place, though it might be a mistake.

Barchart

CEO Andrew Dudum Is Ditching Hims & Hers Stock. Should You?

Insider selling tests investor confidence as Hims & Hers faces valuation pressure and shifting GLP-1 momentum.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Wall Street Journal

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.